Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations
| العنوان: | Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations |
|---|---|
| المؤلفون: | Leonidas D. Arvanitis, Marwan Fakih, Marianna Koczywas, Tamara Mirzapoiazova, Karen L. Reckamp, Jasmine A. McQuerry, Ravi Salgia, Prakash Kulkarni, Isa Mambetsariev, Martin Sattler, Yuan Yuan, Ziad Khan, Susan E. Yost, Andrea Bild, Erminia Massarelli, Sumanta K. Pal, Jeremy Fricke, Raju Pillai, Rebecca Pharaon |
| المصدر: | Future Science OA |
| بيانات النشر: | Future Science Ltd, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | business.industry, Immune microenvironment, medicine.medical_treatment, Immune markers, solid tumors, targeted therapy, Inhibitory postsynaptic potential, Targeted therapy, immune markers, MET, NanoString, Cancer research, Medicine, business, Research Article, Biotechnology |
| الوصف: | The implication of MET alterations in solid tumors and the immune microenvironment remains elusive. Formalin-fixed, paraffin-embedded samples of 21 patients with solid tumors harboring MET alterations were used for immunohistochemical staining. Extracted RNA was analyzed with the NanoString nCounter human PanCancer immune profiling panel (NanoString Technologies, Inc., WA, USA). Patients were diagnosed with lung (n = 10), breast (n = 5), genitourinary (n = 3) or colorectal cancer (n = 3). Eleven had a MET missense mutation, four had an exon 14 splice site mutation and six had MET amplification. CD6, CCL19, CD40LG, XCR1, MAGEA1, ATM and CCL19 genes were significantly differentially expressed in MET-altered cancers. MET alterations may have a role in various solid tumors as potential therapeutic targets and combination therapy candidates with immune checkpoint inhibitors. Lay abstract MET is a receptor for growth signals that keeps cells alive and healthy. However, some tumors have changes in MET that allow for uncontrollable cell growth. Patients with MET-altered tumors may benefit from treatments targeting this gene, but eventually they become resistant to the treatments. Thus, there is a need to identify additional therapies for this patient population. The authors tested immune gene expression in tumors with MET alterations to determine if these patients would benefit from a new class of treatments called immunotherapies and found that patients with and without MET changes had differences in immune gene expression. |
| تدمد: | 2056-5623 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef3d0df7d67d83d658ad1a67344b9ecbTest https://doi.org/10.2144/fsoa-2020-0159Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....ef3d0df7d67d83d658ad1a67344b9ecb |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20565623 |
|---|